InMed Pharmaceuticals Inc Stock Price Today (NSE: INM)
Fundamental Score
InMed Pharmaceuticals Inc Share Price Live NSE/BSE & Institutional Fundamental Analysis
InMed Pharmaceuticals Inc share price today is ₹169.90, up +0.00% on NSE/BSE as of 17 February 2026. InMed Pharmaceuticals Inc (INM) is a Small-cap company in the Furniture, Home Furnishing sector with a market capitalisation of ₹388.24 (Cr). The 52-week high for INM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 35.59x, INM is currently trading below its industry average P/E of 39.98x. The company has a Return on Equity (ROE) of 19.56% and a debt-to-equity ratio of 0.71.
InMed Pharmaceuticals Inc Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
InMed Pharmaceuticals Inc Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
InMed Pharmaceuticals Inc Share Price: A Financial Stability Analysis
The Indian furniture and home furnishing sector is experiencing a shift towards branded players, suggesting a growing consumer preference for quality and reliability. This financial analysis delves into the stability of InMed Pharmaceuticals Inc share price, currently trading at ₹171.100006. The analysis incorporates data points like Price-to-Earnings (PE) ratio, Return on Capital Employed (ROCE), and comparison against sector peers to assess its financial health. This evaluation is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, to ensure a thorough examination of the company's financials.
InMed Pharmaceuticals Inc exhibits a PE ratio of 35.59, which is a significant metric in understanding investor sentiment and valuation relative to its earnings. A high PE ratio could indicate market optimism regarding future growth potential. The company's ROCE of 21.67% is a critical factor. This strong ROCE indicates that InMed Pharmaceuticals Inc is effectively generating profits from its invested capital. A consistently high ROCE creates a competitive advantage or economic moat, as it suggests superior operational efficiency and profitability compared to competitors, allowing for reinvestment and further growth. This profitability is particularly important in a sector becoming more focused on established brands and consistent quality.
When evaluating InMed Pharmaceuticals Inc, it's essential to consider its position relative to its peers, such as
Hardwyn India Ltd. While both companies operate within related industries, differences in management quality and operational strategies may impact financial performance. A comparison between InMed Pharmaceuticals Inc and Hardwyn India Ltd regarding management quality could reveal insights into long-term growth potential and risk management effectiveness. Deeper dives into the financial reporting behaviour and capital allocation are required for this observation.Analyzing InMed Pharmaceuticals Inc's financial stability requires an in-depth assessment of various factors, including its PE ratio, ROCE, and competitive landscape. The 21.67% ROCE, if sustained, could contribute significantly to building a strong economic moat. This observational analysis forms part of a larger, data-driven assessment of InMed Pharmaceuticals Inc's overall financial health and stability within the dynamic Indian market.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
InMed Pharmaceuticals Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INM across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Return on Equity (19.56%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.67%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Revenue Growth (24.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (10.41x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.54%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
2 factors identified
Profit Decline Concern (-25.48%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 5.26%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
InMed Pharmaceuticals Inc Financial Statements
Comprehensive financial data for InMed Pharmaceuticals Inc including income statement, balance sheet and cash flow
About INM (InMed Pharmaceuticals Inc)
InMed Pharmaceuticals Inc (INM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Furniture, Home Furnishing sector with a current market capitalisation of ₹388.24 (Cr). InMed Pharmaceuticals Inc has delivered a Return on Equity (ROE) of 19.56% and a ROCE of 21.67%. The debt-to-equity ratio stands at 0.71, reflecting the company's capital structure. Investors tracking INM share price can monitor key metrics including P/E ratio, promoter holding of 68.54%, and quarterly earnings growth.
Company Details
INM Share Price: Frequently Asked Questions
What is the current share price of InMed Pharmaceuticals Inc (INM)?
As of 17 Feb 2026, 10:11 am IST, InMed Pharmaceuticals Inc share price is ₹169.90. The INM stock has a market capitalisation of ₹388.24 (Cr) on NSE/BSE.
Is INM share price Overvalued or Undervalued?
INM share price is currently trading at a P/E ratio of 35.59x, compared to the industry average of 39.98x. Based on this relative valuation, the InMed Pharmaceuticals Inc stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of INM share price?
The 52-week high of INM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the InMed Pharmaceuticals Inc share price?
Key factors influencing INM share price include quarterly earnings growth (Sales Growth: 24.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is InMed Pharmaceuticals Inc a good stock for long-term investment?
InMed Pharmaceuticals Inc shows a 5-year Profit Growth of N/A% and an ROE of 19.56%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.71 before investing in INM shares.
How does InMed Pharmaceuticals Inc compare with its industry peers?
InMed Pharmaceuticals Inc competes with major peers in the Furniture, Home Furnishing. Investors should compare INM share price P/E of 35.59x and ROE of 19.56% against the industry averages to determine competitive standing.
What is the P/E ratio of INM and what does it mean?
INM share price has a P/E ratio of 35.59x compared to the industry average of 39.98x. Investors pay ₹36 for every ₹1 of annual earnings.
How is INM performing according to Bull Run's analysis?
INM has a Bull Run fundamental score of 32.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does INM belong to?
INM operates in the Furniture, Home Furnishing industry. This classification helps understand the competitive landscape and sector-specific trends affecting InMed Pharmaceuticals Inc share price.
What is Return on Equity (ROE) and why is it important for INM?
INM has an ROE of 19.56%, which indicates excellent management efficiency. ROE measures how efficiently InMed Pharmaceuticals Inc generates profits from shareholders capital.
How is INM debt-to-equity ratio and what does it indicate?
INM has a debt-to-equity ratio of 0.71, which indicates moderate leverage that should be monitored.
What is INM dividend yield and is it a good dividend stock?
INM offers a dividend yield of 0.09%, meaning you receive ₹0.09 annual dividend for every ₹100 invested in InMed Pharmaceuticals Inc shares.
How has INM share price grown over the past 5 years?
INM has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in INM and why does it matter?
Promoters hold 68.54% of INM shares, with 0.63% pledged. High promoter holding often indicates strong management confidence in InMed Pharmaceuticals Inc.
What is INM market capitalisation category?
INM has a market capitalisation of ₹388 crores, placing it in the Small-cap category.
How volatile is INM stock?
INM has a beta of N/A. A beta > 1 suggests the InMed Pharmaceuticals Inc stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is INM operating profit margin trend?
INM has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is INM quarterly performance?
Recent quarterly performance shows InMed Pharmaceuticals Inc YoY Sales Growth of 24.29% and YoY Profit Growth of -25.48%.
What is the institutional holding pattern in INM?
INM has FII holding of 5.26% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the InMed Pharmaceuticals Inc stock.